Thu, Apr 17, 2014, 5:16 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MultiCell Technologies, Inc. Message Board

  • hznp_holder hznp_holder Aug 30, 2013 11:27 AM Flag

    MCET-125 was effective in phase IIa trial... P value 0.0005

    MCT-125

    MCT-125 is a fixed dose combination therapeutic in clinical development, containing lofepramine and L-phenylalanine. Lofepramine is highly specific in acting on noradrenergic neurons to block the reuptake of noradrenaline with little or no direct action of serotoninergic neurons. The synthesis of noradrenaline in noradrenergic neurons is tightly regulated by tyrosine hydroxylase acting as the key rate-limiting step controlling the flow of phenylalanine and tyrosine through to the cataecholamines. Under normal circumstances, administering either phenylalanine or tyrosine does not lead to any increase in the formation of noradrenaline due to the limited activity of tyrosine hydroxylase. MCT-125, which provides phenylalanine to drive the production of noradrenaline and lofepramine to block its reuptake, is thought to lead to the greater availability of noradrenaline in the CNS.

    ****************************************************************************************************************
    MultiCell Technologies Inc. (MCET.OB) Hires Clinical Development and Support Services to Manage MS Fatigue Drug Candidate Study

    Though primary multiple sclerosis-related fatigue (PMSF) affects more than 70 percent of multiple sclerosis (MS) patients, there are limited pharmacological treatment options, and as of yet, no drug has been specifically approved by the U.S. Food and Drug Administration for the treatment of PMSF.

    Biopharmaceutical company MultiCell Technologies Inc. (MCET.OB) today announced it will retain Clinical Development & Support Services Ltd. (CDSS) of Cheshire, England to manage its planned phase IIb clinical trial in the UK for MCT-125, MultiCell’s lead drug candidate for treatment of PMSF.

    MCT-125 is a fixed dose, orally administered combination thought to lead decrease fatigue levels in persons with MS.
    In previous phase IIa studies, MCT-125 was tested on 138 patients suffering from PMSF. Results showed
    efficacy within four weeks of administratio

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • . .yes that percentage looks good.
      my wife has had MS for 23 years.
      if it wasn't for adderall which picks her up
      gives her energy for the day,
      . . fatigue would be a huge dragon to fight.

      MCT-125 is the sword in the stone.

      sfsi.

      Sentiment: Buy

 
MCET
0.0013+0.0001(+8.33%)Apr 17 3:54 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.